Biological therapy in IBD: Anti-tumor necrosis factor-alpha and others

Digestive Diseases

Volumn 21, Issue 2, 2003, Pages 180-191

  Schölmerich, Jürgen ^a   Huber, Gertrud ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Anti sense; Crohn's disease; Cytokines; Growth factors; T lymphocytes; Tumor necrosis factor ; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOSPORIN; DACLIZUMAB; HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G1; INFLIXIMAB; KERATINOCYTE GROWTH FACTOR; MESALAZINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NATALIZUMAB; OLIGONUCLEOTIDE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GROWTH FACTOR; RECOMBINANT INTERLEUKIN 1; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 18; RECOMBINANT INTERLEUKIN 2; SALAZOSULFAPYRIDINE; SEMAPIMOD; STEROID; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG;

ASPERGILLOSIS; BIOLOGICAL THERAPY; CELL ADHESION; CELL MIGRATION; CLINICAL TRIAL; CROHN DISEASE; DOSE RESPONSE; DRUG EFFECT; ENTERITIS; HEADACHE; HISTOPLASMOSIS; HUMAN; IMMUNOMODULATION; INFECTION; LEUKAPHERESIS; LISTERIOSIS; NAUSEA; NONHUMAN; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; REVIEW; SEPSIS; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUBERCULOSIS; ULCERATIVE COLITIS; VERTIGO;

CELL ADHESION; CELL MOVEMENT; CYTOKINES; GROWTH SUBSTANCES; HUMANS; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASES; LYMPHOCYTE ACTIVATION; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0142187683     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073249     Document Type: Review

References (85)

1. Holtmann M, Mudter J, Galle PR, Neurath MF: Das mukosale Immunsystem: Wie klar ist die Pathophysiologie? Internist 2002;43:1343-1353.
2. Schreiber S, Hampe J, Grebe J, Nikolaus S, Stoll M, Fölsch UR: Genetik und Umwelt: Ist das Bild klarer geworden? Internist 2002;43:1335-1342.
3. Softley A, Clamp SE, Watkinson G, Bouchier IA, Myren J, de Dombal FT: The natural history of inflammatory bowel disease: Has there been a change in the last 20 years? Scand J Gastroenterol Suppl 1988;144:20-23.
4. Langholz E, Munkholm P, Davidsen M, Binder V: Course of ulcerative colitis: Analysis of changes in disease activity over years. Gastroenterology 1994;107:3-11.
5. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ: The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology 2001;121:255-260.
6. Gasché C, Schölmerich J, Brynskow J, D'Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ, Sutherland LR: A simple classification of Crohn's disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna, 1998. Inflamm Bowel Dis 2000;6:8-15.
7. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-624.
8. Cominelli F, Kam L: Inflammatory mediators of inflammatory bowel disease. Curr Opin Gastroenterol 1993;9:534-543.
9. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-1035.
10. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (Infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999:117:761-769.
11. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P: ACCENT I Study Group. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359:1541-1549.
12. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
13. Sands B, Van Deventer S, Bernstein C, Kamm M, Rachmilewitz D, Chey W, Lashner B, Wolf D, Blank M, Wild G, Fedorak R, Feagan B, Anderson F, Marsters P, Rutgeerts P: Long-term treatment of fistulizing Crohn's disease: Response to infliximab in the ACCENT II trial through 54 weeks. Gastroenterology 2002;122:A81-A82.
14. Van Bodegraven AA, Sloots CE, Felt-Bersma RJ, Meuwissen SG: Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum 2002;45:39-45.
15. Glück T, Reng M, Linde HJ, Müller-Ladner U, Schölmerich J: Anti-TNF therapy and Listeria monocytogenes infection: Report of two cases. Arthritis Rheum 2002;46:2255-2257.
16. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104.
17. Lügering A, Schmidt M, Lügering N, Pauels HG, Domschke W, Kucharzik T: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145-1157.
18. Ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-211.
19. Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-1785.
20. Echtenacher B, Falk W, Männel DN, Krammer PH: Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990;145:3762-3766.
21. Probert CS, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Arnott ID, Forbes A: Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: A randomised controlled trial. Gut 2003;52:998-1002.
22. Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CD, Salzberg B, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Hanauer SB: A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease. Gastroenterology 2000;118:A655.
23. Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR: CDP571 Crohn's Disease Study Group. An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial. Gastroenterology 2001;120:1330-1338.
24. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, Holmes G, Long R, Forbes A, Kamm MA: Randomized controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 1997;349:521-524.
25. Evans RC, Clarke L, Heath P, Stephens S, Morris AI, Rhodes JM: Treatment of ulcerative colitis with an engineered human anti-TNFα antibody CDP571. Aliment Pharmacol Ther 1997;11:1031-1035.
26. Schreiber S, Rutgeerts P, Fedorak R, Khaliq-Kareemi M, Kamm MA, Patel J, and the CDP870 Crohn's Disease Study Group: CDP870, a humanized anti-TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology 2003;124:A61.
27. D'Haens G, Swijsen C, Noman M, Lemmens L, Ceuppens J, Agbahiwe H, Geboes K, Rutgeerts P: Etanercept in the treatment of active refractory Crohn's disease: A single-center pilot trial. Am J Gastroenterol 2001;96:2564-2568.
28. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR: Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-1094.
29. Rutgeerts P, Lemmens L, Van Assche G, Noman M, Borghini-Fuhrer I, Goedkoop RJ: Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): Results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 2003;17:185-192.
30. Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, Macpherson B, Tytgat G, Peppelenbosch M, Van Deventer S: Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002;122:7-14.
31. Conner EM, Grisham MB: Inflammation, free radicals, and antioxidants. Nutrition 1996;12:274-277.
32. Herfarth H, Brand K, Rath HC, Rogler G, Schölmerich J, Falk W: Nuclear factor-κB activity and intestinal inflammation in dextran sulphate sodium (DSS)-induced colitis in mice is suppressed by gliotoxin. Clin Exp Immunol 2000;120:59-65.
33. Neurath MF, Pettersson S, Meyer zum Büschenfelde KH, Strober W: Local administration of antisense phosporothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat Med 1996;2:998-1004.
34. Löfberg R, Neurath M, Ost A, Pettersson S: Topical NFκB p65 antisense oligonucleotides in patients with active distal colonic IBD. A randomised, controlled pilot trial. Gastroenterology 2002;122:A60.
35. Schreiber S, Heinig T, Thile HG, Raedler A: Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995;108:1434-1444.
36. Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, Hanauer S, Kilian A, Cohard M, LeBeaut A, Feagan B: The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology 2000;119:1473-1482.
37. Fedorak RN, Nielsen OH, Williams NC, Malchow H, Forbes A, Stein B, Wild GE, Lashner B, Renner EL, Buchman A, Hardi R: Human recombinant interleukin-10 is safe and well tolerated but does not induce remission in steroid dependent Crohn's disease. Gastroenterology 2001;120:A127.
38. Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S, Jacyna M, Lashner BA, Gangl A, Rutgeerts P, Isaacs K, van Deventer SJ, Koningsberger JC, Cohard M, Le-Beaut A, Hanauer SB: Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 2000;119:1461-1472.
39. Colombel JF, Rutgeerts P, Malchow H, Jacyna M, Nielsen OH, Rask-Madsen J, Van Deventer S, Ferguson A, Desreumaux P, Forbes A, Geboes K, Melani L, Cohard M: Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 2001;49:42-46.
40. Schreiber S, Fedorak RN, Wild G, Gangl A, Targan S, Jacyna M, Wright JP, Kilian A, Cohard M, Lebeault A, Tremaine WJ: Ulcerative Colitis IL-10 Cooperative Study Group. Safety and tolerance of rHuIL-10 treatment in patients with mild/moderate active ulcerative colitis. Gastroenterology 1998;114:A1080-A1081.
41. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000;289:1352-1355.
42. Herfarth H, Schölmerich J: IL-10 therapy in Crohn's disease: At the crossroads. Treatment of Crohn's disease with the anti-inflammatory cytokine interleukin 10. Gut 2002;50:146-147.
43. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W: Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-1290.
44. Kojouharoff G, Hans W, Obermeier F, Männel DN, Andus T, Schölmerich J, Gross V, Falk W: Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 1997;107:353-358.
45. Rutgeerts P, Reinisch W, Colombel JF, Gendre JP, van Deventer S, Oldenburg B, Modigliani R, Layug B, Cheng M, O'Connor J, Levitt D: Preliminary results of a phase I/II study of HuZAF, an anti-IFN-γ monoclonal antibody, in patients with moderate to severe active Crohn's disease. Gastroenterology 2002;122:A61.
46. Merger M, Herfarth H, Schölmerich J, Andus T, Färber L: Discussion on the biologic therapy of inflammatory bowel disease. Gastroenterology 2003;124:2005-2006.
47. Van Assche G, Dalle I, Noman M, Aerden I, Swijsen C, Asnong K, Maes B, Ceuppens J, Geboes K, Rutgeerts P: A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003;98:369-376.
48. Reinisch W, Nahavandi H, Santella R, Zhang Y, Gasché C, Moser G, Waldhör T, Gangl A, Vogelsang H, Knobler R: Extracorporeal photochemotherapy in patients with steroid-dependent Crohn's disease: A prospective pilot study. Aliment Pharmacol Ther 2001;15:1313-1322.
49. Deusch K, Mauthe B, Reiter C, Rietmüller G, Classen M: CD4-antibody treatment of inflammatory bowel disease: One-year follow-up. Gastroenterology 1993;104:A691.
50. Stronkhorst A, Radema S, Yong SL, Bijl H, ten Berge IJ, Tytgat GN, van Deventer SJ: CD4 antibody treatment in patients with active Crohn's disease: A phase 1 dose finding study. Gut 1997;40:320-327.
51. Canva-Delcambre V, Jacquot S, Robinet E, Lemann M, Drouet C, Labalette M, Dessaint JP, Bengoufa D, Rabian C, Modigliani R, Wijdenes J, Revillard JP, Colombel JF: Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody. Aliment Pharmacol Ther 1996;10:721-727.
52. Emmrich J, Seyfarth M, Liebe S, Emmrich F: Anti-CD4-antibody treatment in inflammatory bowel disease without a long CD4+-cell depletion. Gastroenterology 1995;108:A815.
53. Podolsky DK, Lobb R, King N, Benjamin CD, Pepinsky B, Sehgal P, deBeaumont M: Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest 1993;92:372-380.
54. Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, Donoghue S, Greenlees C, Subhani J, Amlot PL, Pounder RE: A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-274.
55. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S, Natalizumab Pan-European Study Group: Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32.
56. Gordon FH, Hamilton MI, Donoghue S, Amlot PL, Greenlees C, Rowley-Jones D, Pounder RE: Treatment of active ulcerative colitis with a recombinant humanised antibody to α4 integrin (Antegren™). Gastroenterology 1999;116:A726.
57. Hesterberg PE, Winsor-Hines D, Briskin MJ, Soler-Ferran D, Merrill C, Mackay CR, Newman W, Ringler DJ: Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin α4β7. Gastroenterology 1996;111:1373-1380.
58. Feagan B, Greenberg G, Wild G, McDonald J, Fedorak R, Pare P, Kishimoto K, Guitterez-Ramos JC, Krop J, Vandervoort M: A randomized controlled trial of a humanized α4β7 antibody in ulcerative colitis. Gastroenterology 2003;125:606.
59. Feagan BG, Greenberg G, Wild G, McDonald JWD, Fedorak R, Pare P, Kishimoto K, Gutierrez-Ramos JC, Krop J: Efficacy and safety of a humanized α4β7 antibody in active Crohn's disease. Gastroenterology 2003;124:A25-A26.
60. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, Shanahan WR Jr: A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998;114:1133-1142.
61. Schreiber S, Nikolaus S, Malchow H, Kruis W, Lochs H, Raedler A, Hahn EG, Krummenerl T, Steinmann G: The German ICAM-1 Study Group. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 2001;120:1339-1346.
62. Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, Tami J, Yu R, Gibiansky E, Shanahan WR: ISIS 2302-CS9. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alica-forsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002;51:30-36.
63. Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford RJ: Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003;349:350-357.
64. Sandborn WJ, Sands BE, Wolf DC, Valentine J, Safdi M, Katz S, Isaacs KL, Wruble LD, Katz JA, Present DH, Loftus EV Jr, Odenheimer DJ, Hanauer SB: Repifermin (keratinocyte growth factor 2) for the treatment of active ulcerative colitis: A randomized, double-blind, placebo-controlled, dose-escalation trial. Gastroenterology 2002;122:A61.
65. Hanauer SB, Baert FJ, Robinson M: Interferon treatment in mild to moderate active Crohn's disease: Preliminary results in an open label study, Gastroenterology 1994;106:A696.
66. Madsen SM, Schlichting P, Davidsen B, Nielsen OH, Federspiel B, Riis P, Munkholm P: An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am J Gastroenterol 2001;96:1807-1815.
67. Gasché C, Reinisch W, Vogelsang H, Potzi R, Markis E, Micksche M, Wirth HP, Gangl A, Lochs H: Prospective evaluation of interferon-α in treatment of chronic active Crohn's disease. Dig Dis Sci 1995;40:800-804.
68. Tilg H, Vogelsang H, Ludwiczek L, Lochs H, Kaser A, Colombel JF, Ulmer H, Rutgeerts P, Krüger S, Cortot A, D'Haens G, Harrer M, Gaschë C, Wrba F, Kuhn I, Reinisch W: A randomised placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut, in press.
69. Nikolaus S, Rutgeerts P, Fedorak RN, Steinhart H, Wild GE, Theuer D, Schreiber S, Moehrle JJ, Goedkoop RJ: Recombinant human interferon-beta (IFNβ-1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology 2001;120:A454.
70. Musch E, Jüntgen C, Witzke O, Schwarck H, Hüttmann H: Successful therapy of colitis ulcerosa by beta-interferon. Gut. 1995;37:A141.
71. Musch E, Raedler A, Andus T, Kruis W, Schreiber S, Lorenz A, Krakamp B, Malchow H, Feurle G, Sezekly G, Krizova V: A phase II placebo-controlled, randomized, multicenter study to evaluate efficacy and safety of interferon beta-1A in patients with ulcerative colitis. Gastroenterology 2002:A431.
72. Korzenik JR, Dieckgraefe BK: Immune stimulation in Crohn's disease: Safety and efficacy of rhuGM-CSF for the treatment of active Crohn's disease. Gastroenterology 2001;120:A277-A278.
73. Vaughan D, Drumm B: Treatment of fistulas with granulocyte colony-stimulating factor in a patient with Crohn's disease. N Engl J Med 1999;340:239-240.
74. Sands BE, Bank S, Sninsky CA, Robinson M, Katz S, Singleton JW, Miner PB, Safdi MA, Galandiuk S, Hanauer SB, Varilek GW, Buchman AL, Rodgers VD, Salzberg B, Cai B, Loewy J, De Bruin MF, Rogge H, Shapiro M, Schwertschlag US: Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999;117:58-64.
75. Sands BE, Winston BD, Salzberg B, Safdi M, Barish C, Wruble L, Wilkins R, Shapiro M, Schwertschlag US: RHIL-11 Crohn's Study Group. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 2002;16:399-406.
76. Slonim AE, Bulone L, Damore MB, Goldberg T, Wingertzahn MA, McKinley MJ: A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med 2000;342:1633-1637.
77. Andus T, Klebl F, Rogler G, Bregenzer N, Schölmerich J, Straub RH: Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone (DHEA): A pilot study. Aliment Pharmacol Ther 2003;17:409-414.
78. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, Wu GD: A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammation response. J Clin Invest 1999;104:383-389.
79. Lewis JD, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, Fogt F, Furth EE, Demissie EJ, Hurd LB, Su CG, Keilbaugh SA, Lazar MA, Wu GD: An open-label trial of the PPARγ ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 2001;96:3323-3328.
80. Sandborn WJ, Targan SR: Biologic therapy of inflammatory bowel disease. Gastroenterology 2002;122:1592-1608.
81. Schölmerich J: Future developments in diagnosis and treatment of inflammatory bowel disease. Hepatogastroenterology 2000;47:101-114.
82. Stallmach A, Wittig BM, Moser C, Fischinger J, Duchmann R, Zeitz M: Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease (IBD). Gut 2003;52:377-382.
83. Obermeier F, Dunger N, Deml L, Herfarth H, Schölmerich J, Falk W: CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice. Eur J Immunol 2002;32:2084-2092.
84. Rutgeerts P, Van Assche G, D'Haens G, Baert F, Noman M, Aerden I, Geboes K, D'Hoore A, Penninckx F: Ornidazole for prophylaxis of postoperative Crohn's disease: Final results of a double blind placebo controlled trial. Gastoenterology 2002;122:A80.
85. Kruis W, Fric P, Stolte M: The Mutaflor Study Group. Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli Nissle 1917 and with standard mesalamine. Gastroenterology 2001;120:A127.